Product Information
Registration Status: ActiveSIN09666P
TONIN COUGH SYRUP S is approved to be sold in Singapore with effective from 1998-07-03. It is marketed by SATO PHARMACEUTICAL (SINGAPORE) PTE LTD, with the registration number of SIN09666P.
This product contains Noscapine 300mg/30ml, and Guaifenesin 60mg/30ml in the form of SYRUP. It is approved for ORAL use.
This product is manufactured by SATO PHARMACEUTICAL CO LTD in JAPAN.
It is an Over-the-counter Medicine that can be freely obtained from any retailer
Product Reference
Important Note: For generic product, the SPC/PIL provided may not be brand specific.
{{/items}} {{^items}}Indication
Investigated for use/treatment in lymphoma (non-hodgkin's), leukemia (lymphoid), cancer/tumors (unspecified), and multiple myeloma.
Mechanism of Action
Noscapine's antitussive effects appear to be primarily mediated by its sigma receptor agonist activity. Evidence for this mechanism is suggested by experimental evidence in rats. Pretreatment with rimcazole, a sigma specific antagonist, causes a dose-dependent reduction in antitussive activity of noscapine.
Active Ingredient/Synonyms
CB3304 | Noscapine |
Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.
Description
An expectorant that also has some muscle relaxing action. It is used in many cough preparations. [PubChem]
Indication
Used to assist the expectoration of phlegm from the airways in acute respiratory tract infections.
Mechanism of Action
Guaifenesin may act as an irritant to gastric vagal receptors, and recruit efferent parasympathetic reflexes that cause glandular exocytosis of a less viscous mucus mixture. Cough may be provoked. This combination may flush tenacious, congealed mucopurulent material from obstructed small airways and lead to a temporary improvement in dyspnea or the work of breathing.
Pharmacokinetics
- Absorption
- Rapidly absorbed from the GI tract
- Distribution
- Metabolism
- Rapidly hydrolyzed (60% within seven hours) and then excreted in the urine, with beta-(2-methoxyphenoxy)-lactic acid as its major urinary metabolite.
- Elimination
Toxicity
LD50 1510 mg/kg (rat, oral)
Active Ingredient/Synonyms
Glyceryl guaiacolate | guaiphenesin | Hustosil | Guaifenesin |
Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.